Olvos®probiotic yogurt starter culture
Olvos® is built exclusively around clinically studied probiotics backed by more than 180 clinical studies for targeted health support.
Olvos® composition & key characteristics
Olvos® yogurt starter culture contains 8 premium probiotic strains.
Olvos® delivers more than 7 trillion CFU per Kg of yogurt.
The health benefits are supported by 180+ clinical studies and 680+ original publications.
Olvos® yogurt is designed to contribute to homeostasis across a wide spectrum of disorders.
Olvos® homemade yogurt supports the immune system and provides beneficial bacteria to the gastrointestinal flora.
The 8 probiotic strains work closely as a team to perform what single strains cannot do.
Olvos® yogurt provides high counts of clinically documented probiotics at unrivalled low cost.
Clinical studies supporting the Olvos® probiotic strains
NCFM®
Lactobacillus acidophilus
HN019®
Bifidobacterium lactis
HN001®
Lactobacillus rhamnosus
Bi-07®
Bifidobacterium animalis
LPC-37®
Lactobacillus paracasei
BL-04®
Bifidobacterium lactis
ST-21®
Streptococcus thermophilus
LB-87®
Lactobacillus bulgaricus
Documented effects in clinical studies of each individual probiotic
- NCFM® is one of the most extensively studied probiotic strains in the world. It has been extensively used since the 1970s.
- NCFM® is recognized for its ability to survive gastrointestinal transit and temporarily persist within the intestinal environment, supporting continued functional activity during consumption.
- Synergistic functionality when combined with HN019® Bifidobacterium lactis, HN001® Lactobacillus rhamnosus, Bi-07® Bifidobacterium animalis, and BL-04® Bifidobacterium lactis.
- Improvement of digestive comfort, reduction of bloating and abdominal discomfort, support of bowel regularity, and modulation of gut microbiota composition.
- Strengthening of intestinal barrier integrity, reduction of intestinal permeability, and modulation of inflammatory signaling pathways.
- Support of visceral pain regulation through gut–brain signaling mechanisms, enhancement of innate and mucosal immune responses, and antimicrobial activity against pathogenic microorganisms, like C. difficile.
- HN019® was isolated from commercial yogurt cultures in the late 1980s.
- HN019® is recognized for its survival through gastrointestinal transit and its capacity to exert transient functional activity within the intestinal tract during consumption.
- Synergistic functionality when combined with NCFM® Lactobacillus acidophilus, HN001® Lactobacillus rhamnosus, LPC37® Lactobacillus paracasei, and Bi-07® Bifidobacterium animalis.
- Improvement of digestive health, enhancement of bowel regularity, reduction of intestinal transit time, and support of relief from functional gastrointestinal discomfort and constipation.
- Modulation of gut microbiota composition, enhancement of beneficial bacterial populations, and support of intestinal microbial balance.
- Stimulation of innate and cellular immune responses, enhancement of natural killer cell activity and phagocytic function, and support of mucosal immune defense.
- Maintenance of gut barrier function, antimicrobial activity against pathogenic microorganisms, and support of resistance to gastrointestinal infections.
- HN001® was isolated from commercial dairy products during the 1980s.
- HN001® is recognized for its ability to survive gastrointestinal transit and temporarily persist within the intestinal environment, supporting continued functional activity during consumption.
- Synergistic functionality when combined with NCFM® Lactobacillus acidophilus, HN019® Bifidobacterium lactis, LPC37® Lactobacillus paracasei, and Bi-07® Bifidobacterium animalis.
- Probiotic strain associated with multiple health benefits involving immune, gastrointestinal, dermatological, and maternal–infant health domains.
- Support of digestive health, modulation of intestinal microbiota composition, enhancement of gastrointestinal comfort, and support of resistance against gastrointestinal and respiratory infections.
- Stimulation of innate and adaptive immune responses, enhancement of natural killer cell activity, modulation of cytokine production, and support of mucosal immune defense.
- Several influential randomized controlled trials during 2000s-2010s showed that HN001® reduced the risk and severity of atopic eczema and allergic sensitization in infants and children, particularly following maternal and early-life supplementation.
- Support of maternal psychological well-being, including reduction of postpartum stress, anxiety, and depressive symptoms.
- Maintenance of gut barrier integrity, antimicrobial activity against pathogenic microorganisms, and transient functional colonization during continued intake.
- Bi-07® emerged from probiotic screening research programs in 1990s.
- Bi-07® is recognized for its survival through gastrointestinal transit and its capacity for transient functional persistence during continued intake.
- Synergistic functionality when combined with NCFM® Lactobacillus acidophilus, BL-04® Bifidobacterium lactis, and LPC37® Lactobacillus paracasei.
- Reduction of abdominal bloating and gastrointestinal discomfort, modulation of intestinal microbiota composition, and enhancement of beneficial bacterial populations within the gut.
- Bi-07® has also been associated with support of bowel regularity, improvement of gastrointestinal function, and maintenance of intestinal microbial balance.
- Enhancement of innate and mucosal immune responses, modulation of cytokine signaling, and support of resistance against common respiratory tract infections.
- Support of gut barrier integrity, antimicrobial activity against undesirable microorganisms.
- Support of healthy aging through microbiota and immune regulation.
- LPC-37® emerged during probiotic screening programs in the late 1990s.
- LPC-37® is recognized for its gastrointestinal survival, acid and bile tolerance, and transient functional persistence during gastrointestinal transit.
- Synergistic functionality when combined with NCFM® Lactobacillus acidophilus, HN019® Bifidobacterium lactis, Bi-07® Bifidobacterium animalis, and BL-04® Bifidobacterium lactis.
- LPC-37® is associated with support of stress management, reduction of perceived psychological stress, improvement of emotional well-being, and support of healthy physiological responses to acute and chronic stress exposure.
- Support of sleep quality, mental alertness, and gut–brain axis functionality.
- Modulation of intestinal microbiota composition, enhancement of digestive comfort, maintenance of gut barrier integrity, and support of immune signaling and mucosal defense mechanisms.
- Antimicrobial activity against undesirable microorganisms.
- BL-04® was developed during probiotic screening programs in 1990s.
- BL-04® is recognized for its ability to survive gastrointestinal transit and exert transient functional activity during consumption.
- Synergistic functionality when combined with NCFM® Lactobacillus acidophilus, Bi-07® Bifidobacterium animalis, and LPC37® Lactobacillus paracasei.
- Support of immune system function, enhancement of innate immune responses, and increased resistance to upper respiratory tract infections, particularly during periods of immune stress.
- Reduction in the incidence and duration of common cold symptoms, enhancement of natural immune surveillance mechanisms, and support of systemic immune readiness.
- Modulation of intestinal microbiota composition, support of beneficial bacterial populations, and maintenance of gut microbial balance.
- Support of gastrointestinal function, maintenance of gut barrier integrity, and modulation of mucosal immune signaling.
- Legally required for a product to be classified as yogurt
- Recognized for contribution to lactose digestion
- Modulate gut microbiota and support innate immunity, bowel regularity, protein digestion, release of bioactive peptides.